Health

Regeneron antibody combination therapy reduces the risk of COVID-19 mortality

Recovery trial results show that Regeneron’s intra-trial antibody combination therapy reduces the risk of death in hospitalized patients with severe COVID-19 seronegative.

Results from a randomized assessment of COVID-19 therapy (RECOVERY) show that Regeneron’s ongoing antibody combination therapy reduces the risk of death in hospitalized patients with severe COVID-19 whose immune response does not initiate spontaneously is showing. The test results were announced in a press release on June 16, 2021.

Regeneron’s combination therapy consists of two monoclonal antibodies (casilibimab and imdebimab) that specifically bind to two different sites of the coronavirus peplomer. Previous studies of patients who have not been hospitalized have shown that this treatment reduces viral load, shortens the time to resolution of symptoms, and significantly reduces the risk of hospitalization or death.

Preliminary results from a small trial of inpatients suggested that the combination therapy provided clinical benefit to inpatients who did not initiate a natural immune response (seronegative). The recovery trial included 9785 patients admitted with COVID-19. This is a sufficient population of patients to determine if treatment reduces mortality.

Approximately one-third of the patients included in the study were seronegative at baseline. For these patients, combination therapy was found to significantly reduce the primary outcome of 28-day mortality. This result could not be compared to patients who were serum positive at baseline.

“These results are very exciting. It was hoped that the combination of antibodies targeting the SARS-CoV-2 virus could alleviate the worst symptoms of COVID-19. However, late COVID- There was great uncertainty about the value of antiviral therapy in 19 diseases, “said a professor of emerging infectious diseases at the University of Oxford’s Nafield School of Medicine, a recovery trial in a press release. “It’s great to know that even with advanced COVID-19 disease, targeting the virus can reduce the mortality rate of patients who fail to initiate their own antibody response.”

“We have found that this combination of antibodies is not only bad for the virus, but also good for the most ill patients who have failed to initiate their own natural immune response,” added Sir Martin Landley, a professor of medical epidemiology. I did. In the press release, he is a co-principal researcher with the Nafield Department of Population Health at Oxford University. “This is great news. This is the first time that a life-saving antiviral treatment for a COVID-19 patient in the hospital has been shown. A big thank you to the many NHS staff and patients who contributed to today’s discovery. I am. “

Source: Oxford University

ExBulletin

Regeneron antibody combination therapy reduces the risk of COVID-19 mortality